Abstract
Success in therapy for adults with acute lymphoblastic leukemia (ALL) has lagged behind that of children with ALL. However, the application of pediatric-intensive regimens to young and middle-aged adults suggests improved outcomes without excessive toxicity. A promising area in the treatment of adult ALL is the addition of monoclonal antibodies in various forms to chemotherapy in adults with ALL. New chemotherapeutic approaches show promise, and early-phase clinical trials with these drugs are under way.
Original language | English (US) |
---|---|
Pages (from-to) | 1303-1317 |
Number of pages | 15 |
Journal | Hematology/Oncology Clinics of North America |
Volume | 25 |
Issue number | 6 |
DOIs | |
State | Published - Dec 2011 |
Keywords
- Acute lymphoblastic leukemia
- Chemotherapy
- Kinase inhibitor therapy
- Monoclonal antibody therapy
ASJC Scopus subject areas
- Hematology
- Oncology